Publications by authors named "D Burdette"

Article Synopsis
  • The study describes four cases of Responsive Neurostimulation (RNS) targeting the bilateral pulvinar nuclei in patients with drug-resistant epilepsy, highlighting that this method could benefit those with bilateral multifocal epilepsy due to the PUL's extensive connectivity.
  • Conducted at two medical centers, the research involved patients implanted with bilateral PUL RNS between 2019 and 2022, detailing target selection, device programming, and clinical outcomes.
  • The results showed significant reductions in disabling seizures for all patients, with no adverse effects reported, indicating that RNS targeting the PUL might be a safe and effective treatment option for specific epilepsy cases.
View Article and Find Full Text PDF

Messenger RNA (mRNA)-based therapeutics have emerged as a promising modality for various clinical applications, necessitating robust methods for mRNA quantification. This biodistribution study compares the performance of branched DNA and reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) assays for measuring lipid nanoparticle-encapsulated mRNA. Following intravenous administration of nascent peptide imaging luciferase mRNA (1 mg/kg) to rats, mRNA levels in various tissues and serum were quantified using both assays.

View Article and Find Full Text PDF

Following the approval of Epidiolex® (cannabidiol; CBD) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), and tuberous sclerosis complex (TSC), healthcare professionals (HCPs) have had substantial experience in treating patients with Epidiolex. However, confusion still remains among HCPs, caregivers, and patients regarding dosing, drug interactions, safety monitoring, and differentiation between Epidiolex and nonapproved CBD products. To establish consensus recommendations for Epidiolex treatment optimization in LGS, DS, and TSC, a panel of seven HCPs with expertise in epilepsy was convened.

View Article and Find Full Text PDF

Capsid assembly mediated by hepatitis B virus (HBV) core protein (HBc) is an essential part of the HBV replication cycle, which is the target for different classes of capsid assembly modulators (CAMs). While both CAM-A ("aberrant") and CAM-E ("empty") disrupt nucleocapsid assembly and reduce extracellular HBV DNA, CAM-As can also reduce extracellular HBV surface antigen (HBsAg) by triggering apoptosis of HBV-infected cells in preclinical mouse models. However, there have not been substantial HBsAg declines in chronic hepatitis B (CHB) patients treated with CAM-As to date.

View Article and Find Full Text PDF

Regulatory T cells (T) are essential for maintaining immune homeostasis by serving as negative regulators of adaptive immune system effector cell responses. Reduced production or function of T has been implicated in several human autoimmune diseases. The cytokine interleukin 2 plays a central role in promoting T differentiation, survival, and function in vivo and may therefore have therapeutic benefits for autoimmune diseases.

View Article and Find Full Text PDF